Albiglutide: A New GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes

Annals of Pharmacotherapy

Volumn 48, Issue 11, 2014, Pages 1494-1501

  Trujillo, Jennifer M ^a   Nuffer, Wesley ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

albiglutide; GLP 1 receptor agonist; T2D

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBIGLUTIDE; ALBUMIN; DIPEPTIDYL PEPTIDASE IV; GLIMEPIRIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLYCOSYLATED HEMOGLOBIN;

ADD ON THERAPY; DIABETIC PATIENT; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GLUCAGON RELEASE; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN RELEASE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SATIETY; STOMACH EMPTYING; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; AGONISTS; ANALOGS AND DERIVATIVES; BODY WEIGHT; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; DRUG EFFECTS;

BODY WEIGHT; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; RECEPTORS, GLUCAGON;

EID: 84908099303     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014545807     Document Type: Review

References (26)

1. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011:
2. International Diabetes Federation. IDF Diabetes Atlas. 5th ed.Brussels, Belgium: International Diabetes Federation; 2011. http://www.idf.org/diabetesatlas. Accessed April 2, 2014.
3. Inzucchi SE,Bergenstal RM,Buse JB,.Management of hyperglycemia in T2D: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetes Care. 2012;35:1364-1379
4. Bush MA,Matthews JE,De Boever EH,.Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects.Diabetes Obes Metab. 2009;11:498-505
5. Research Triangle Park, NC: Tanzeum; 2014:
6. Baggio LL,Huang Q,Brown TJ,Drucker DJ.A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, GI motility, and glucose homeostasis.Diabetes. 2004;53:2492-2500
7. Matthews JE,Stewart MW,De Boever EH,.Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with T2D.J Clin Endocrinol Metab. 2008;93:4810-4817
8. Seino Y,Nakajima H,Miyahara H,.Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with T2D mellitus.Curr Med Res Opin. 2009;25:3049-3057
9. Rosenstock J,Reusch J,Bush M,Yang F,Stewart M.Potential of albiglutide, a long-acting GLP-1 receptor agonist, in T2D: a randomized controlled trial exploring weekly, biweekly, and monthly dosing.Diabetes Care. 2009;32:1880-1886
10. Seino Y,Inagaki N,Miyahara H,.A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with T2D mellitus.Curr Med Res Opin. 2014;30:1095-1106
11. Bush M,Scott R,Watanalumlerd P,Zhi H,Lewis E.Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive.Postgrad Med. 2012;124 (6): 55-72
12. Reinhardt R,Nauck MA,Stewart M,.HARMONY 2 results at week 52 primary endpoint: once-weekly albiglutide monotherapy for patients with T2D mellitus inadequately controlled with diet and exercise.Diabetologia. 2013;56:S360
13. Rosenstock J,Fonseca VA,Gross JL,.Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.Diabetes Care.:
14. Ahren B,Johnson SL,Stewart M,.HARMONY-3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.Diabetes Care.:
15. Leiter LA,Carr MC,Stewart M,.Once weekly (QW) GLP1 agonist albiglutide (Albi) vs. sitagliptin (Sita) in T2D (T2D) pts with renal impairment (RI): week 26 results.Diabetes. 2013;62:A17
16. Pratley R,Stewart M,Cirkel D,.HARMONY 4: 52-week efficacy of albiglutide vs insulin glargine in patients with T2D mellitus.Diabetologia. 2013;56:S360
17. Pratley RE,Nauck MA,Barnett AH,.Once-weekly albiglutide versus once-daily liraglutide in patients with T2D inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.Lancet Diabetes Endocrinol. 2014;2:289-297
18. Reusch JSM,Perkins C,Ordronneau J,.HARMONY 1 results at week 52 primary endpoint: once-weekly albiglutide vs placebo in patients with T2D mellitus not controlled on pioglitazone ± metformin.Diabetologia. 2013;56:S359
19. Stewart M,Home P,Yang F,.52-Week efficacy of albiglutide vs placebo and vs pioglitazone in triple therapy (background metformin and glimepiride) in patients with T2D: HARMONY 5 study.Diabetologia. 2013;56:S361
20. Martin AA,Johnson SL,Ye J,Rosenstock J.Improved treatment satisfaction with weekly albiglutide vs. thrice daily prandial insulin added to insulin glargine in T2D.Diabetes. 2013;62:A659
21. Martin AA,Johnson SL,Ye J,Pratley E.Treatment satisfaction with albiglutide and liraglutide in patients with T2D uncontrolled with oral therapy.Diabetes. 2013;62:A259
22. Tanzeum (albiglutide) risk evaluation and mitigation strategy. http://www.fda.gov/downloads/Drugs/DrugSafety/-PostmarketDrugSafetyInformationforPatientsandProviders/UCM393986.pdf. Accessed May 26, 2014.
23. Buse JB,Nauck M,Forst T,.Exenatide once weekly versus liraglutide once daily in patients with T2D (DURATION-6): a randomised, open-label study.Lancet. 2013;381:117-124
24. Buse JB,Rosenstock J,Sesti G,.Liraglutide once a day versus exenatide twice a day for T2D: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).Lancet. 2009;374:39-47
25. Buse JB,Drucker DJ,Taylor KL,.DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.Diabetes Care. 2010;33:1255-1261
26. Blevins T,Pullman J,Malloy J,.DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with T2D.J Clin Endocrinol Metab. 2011;96:1301-1310